A prospective pilot study of an elemental nutritional supplement for prevention of oral mucositis during S-1 adjuvant chemotherapy for gastric cancer
| Autor: | Kyoichi Ogata, Hiroyuki Kuwano, Mitsuhiro Yanai, Norimichi Kogure, Erito Mochiki, Toru Yanoma, Akiharu Kimura, Yoshitaka Toyomasu, Masaki Suzuki |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Elemental diet medicine.medical_treatment Pilot Projects Gastroenterology law.invention 0302 clinical medicine Japan Randomized controlled trial Weight loss law Clinical endpoint Prospective Studies Aged 80 and over Nutritional Support Incidence Middle Aged Prognosis Drug Combinations Oncology 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology Median body medicine.symptom Adult Diarrhea Antimetabolites Antineoplastic medicine.medical_specialty Adenocarcinoma Young Adult 03 medical and health sciences Stomach Neoplasms Internal medicine medicine Mucositis Humans Adverse effect Aged Tegafur Food Formulated Stomatitis Chemotherapy business.industry medicine.disease Oxonic Acid Case-Control Studies Surgery business Follow-Up Studies |
| Zdroj: | Surgical Oncology. 29:97-101 |
| ISSN: | 0960-7404 |
| Popis: | Purposes Oral mucositis is one of the most common reasons for discontinuation of S-1 adjuvant chemotherapy after radical gastrectomy. Some studies suggest that nutritional support with amino acids may improve oral mucositis. We conducted a prospective, randomized clinical trial of patients who underwent adjuvant chemotherapy for gastric cancer to examine whether an oral elemental diet prevents chemotherapy associated oral mucositis and body weight loss. Methods Patients were randomly assigned to a group consuming Elental® (the treatment group, n = 11) or a control diet group (n = 11). Patients in the treatment group consumed one pack of Elental® per day during adjuvant chemotherapy. The primary endpoint was the presence and grade of oral mucositis. Secondary endpoints included adherence to Elental® based on the doses recorded in a diary, changes in nutrition parameters, and frequency and severity of adverse events. Results The incidence of oral mucositis was significantly lower in the treatment group (9.1%) than in the control group (27.3%). The median body weight loss in the treatment group was significantly smaller than that in the control group (P = .015). According to Kaplan-Meier estimates the treatment group was significantly associated with high cumulative S-1 continuation rates (log-rank P = .047). Conclusion We conclude that the amino-acid-rich elemental diet Elental® may be useful as a countermeasure for S-1 adjuvant chemotherapy-induced mucositis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect